Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 7/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10707090 | 0.83 | NPSR1 (0.43) | ADORA1ADORA2AADORA2BMYCWDR5 | |
| SCHEMBL5150675 | 0.83 | ADORA1 (0.56) | ADORA1ADORA2AADORA2BHSD17B10 | |
| SCHEMBL10611187 | 0.80 | ADORA1 (0.61) | ADORA1ADORA2AADORA2BMYCWDR5 | |
| SCHEMBL28933575 | 0.78 | ADORA1 (0.43) | ADORA1ADORA2AADORA2BMYCWDR5 | |
| SCHEMBL4468508 | 0.77 | ALDH1A1 (0.46) | ADORA1KDM4EKMT2AMEN1GAA | |
| SCHEMBL9680772 | 0.75 | ADORA1 (0.55) | ADORA1ADORA2A | |
| SCHEMBL23911669 | 0.75 | CUL4A (0.41) | ADORA1ADORA2AADORA2BKDM4EKMT2A | |
| SCHEMBL14697805 | 0.73 | KDR (0.58) | KDM4EKMT2AMEN1CYP1A2GAA | |
| SCHEMBL9649847 | 0.73 | ADORA2A (0.57) | ADORA1ADORA2AADORA2BKDM4EKMT2A | |
| SCHEMBL28697712 | 0.73 | NPC1 (0.53) | ADORA1ADORA2AADORA2BMYCWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227984-B2 | Therapeutically active fused pyrimidine derivatives | UCB PHARMA S.A. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-10-16 | — | — | US | disclosed |
| EP-2744812-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013024291-A2 | THERAPEUTICALLY ACTIVE FUSED PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | HAVCR2, TPMT, PAICS | ADORA1 921/4885ADORA2A 161/4885ADORA2B 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.